Physician profile
Ryan W Weber
NPI 1942434824
$2,520.11
in general payments reported to CMS, 2019-2025
27 companies · $853 in 2025
The $853 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.61 · 2022: $133 · 2023: $523 · 2024: $934 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,310.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $365.30 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $354.48 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $335.67 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $280.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.98 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.59 | 2019-2024 | Jardiance, Synjardy |
| Abbvie INC. | $91.12 | 2022-2024 | |
| Axsome Therapeutics, INC. | $80.80 | 2023-2025 | Auvelity |
| Pfizer INC. | $79.92 | 2023-2025 | |
| Amgen INC. | $72.69 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $68.83 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $65.52 | 2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $62.82 | 2023-2024 | Veozah |
| Edwards Lifesciences Corporation | $53.10 | 2023-2024 | Sapien 3 Ultra Resilia |
| Baxter Healthcare | $52.57 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $41.88 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $39.13 | 2023 | |
| Ibsa Pharma INC. | $34.00 | 2024 | Licart, Tirosint |
| Grifols USA, LLC | $25.41 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $21.04 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $20.75 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.45 | 2022 | |
| Amarin Pharma, INC. | $17.87 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.15 | 2025 | Kristalose |
| Abbott Laboratories | $15.68 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.62 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.